Zobrazeno 1 - 10
of 10 354
pro vyhledávání: '"G, Krebs"'
Autor:
Catterall, William A., Scott, John D.
Publikováno v:
Science, 2010 Jan . 327(5965), 537-537.
Externí odkaz:
https://www.jstor.org/stable/40510175
Autor:
Womack, Steven
Publikováno v:
Studies in Popular Culture, 2002 Apr 01. 24(3), 17-24.
Externí odkaz:
https://www.jstor.org/stable/23414963
Autor:
Matthew G. Krebs, MD, Martin Forster, MD, PhD, Margarita Majem, MD, PhD, Julio Peguero, MD, Wade Iams, MD, Tim Clay, MD, Patricia Roxburgh, MD, PhD, Bernard Doger, MD, PhD, Pawan Bajaj, MD, Andres Barba, MD, Suvini Perera, MS, Christian Mueller, MS, Frédéric Triebel, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 11, Pp 100725- (2024)
Introduction: Eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, triggers antigen-presenting cell and T-cell (CD4+ and CD8+) activation and helps overcome resistance to programmed cell death protein 1 or programmed cell death-l
Externí odkaz:
https://doaj.org/article/12c20e7bd714464f84bdef20677b2f93
Publikováno v:
In Journal of Biological Chemistry 28 October 2005 280(43):e40-e42
Autor:
Alicia-Marie Conway, Simon P. Pearce, Alexandra Clipson, Steven M. Hill, Francesca Chemi, Dan Slane-Tan, Saba Ferdous, A. S. Md Mukarram Hossain, Katarzyna Kamieniecka, Daniel J. White, Claire Mitchell, Alastair Kerr, Matthew G. Krebs, Gerard Brady, Caroline Dive, Natalie Cook, Dominic G. Rothwell
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Cancers of Unknown Primary (CUP) remains a diagnostic and therapeutic challenge due to biological heterogeneity and poor responses to standard chemotherapy. Predicting tissue-of-origin (TOO) molecularly could help refine this diagnosis, with
Externí odkaz:
https://doaj.org/article/d4bcd616a1c54d2c97e8ef0bccad3ec9
Autor:
Kjetil Taskén, Soemeya F. Haj Mohammad, Gro Live Fagereng, Ragnhild Sørum Falk, Åslaug Helland, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Katarina Steen Carlsson, Bettina Ryll, Katriina Jalkanen, Anders Edsjö, Hege G. Russnes, Ulrik Lassen, Ebba Hallersjö Hult, Iwona Lugowska, Jean-Yves Blay, Loic Verlingue, Edvard Abel, Maeve A. Lowery, Matthew G. Krebs, Kristoffer Staal Rohrberg, Kristiina Ojamaa, Julio Oliveira, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation o
Externí odkaz:
https://doaj.org/article/a341b8825c7a4512be06dc2a4bf54da1
Publikováno v:
La Revue administrative, 2004 Jul 01. 57(340), 445-445.
Externí odkaz:
https://www.jstor.org/stable/40772137
Autor:
Sonnabend, Gaby
Francia, Bd. 29 Nr. 3 (2002)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d638a0ae3c36e8145bbd9787c96b6f15
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we rep
Externí odkaz:
https://doaj.org/article/b14be29b81754bafad04d4aa37714251